A Phase 3b Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Moxifloxacin; Moxifloxacin
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors Paratek Pharmaceuticals
- 22 Aug 2024 Status changed from active, no longer recruiting to completed.
- 14 Apr 2024 This study has been completed in Poland, according to European Clinical Trials Database record.
- 14 Mar 2024 Status changed from recruiting to active, no longer recruiting.